首页 / 产品 / 蛋白 / 跨膜蛋白

Recombinant Human CLDN18 protein

  • 中文名: 封闭蛋白18(CLDN18)重组蛋白
  • 别    名: CLDN18;Claudin-18
货号: PA1000-8370
Price: ¥询价
数量:
大包装询价

产品详情

纯度>90%SDS-PAGE.
种属Human
靶点CLDN18
Uniprot No P56856
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间28-80aa
氨基酸序列DQWSTQDLYNNPVTAVFNYQGLWRSCVRESSGFTECRGYFTLLGLPAMLQAVR
预测分子量 32.8 kDa
蛋白标签His tag N-Terminus
缓冲液PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于CLDN18重组蛋白的3篇参考文献示例,涵盖结构、应用及抗体开发方向:

---

1. **文献名称**:*"Expression and purification of recombinant CLDN18.2 for targeted therapy in gastric cancer"*

**作者**:Zhang et al.

**摘要**:成功在大肠杆菌中表达并纯化CLDN18.2重组蛋白,验证其与临床抗体(如Zolbetuximab)的特异性结合,为胃癌靶向治疗开发提供实验基础。

2. **文献名称**:*"Cryo-EM structure of human CLDN18.2 reveals pore-forming motifs"*

**作者**:Müller et al.

**摘要**:通过冷冻电镜解析CLDN18.2的高分辨率结构,阐明其跨膜域构象及细胞旁屏障功能的分子机制,为设计小分子抑制剂提供结构依据。

3. **文献名称**:*"Recombinant CLDN18.2-based monoclonal antibody suppresses tumor growth in preclinical models"*

**作者**:Li et al.

**摘要**:利用重组CLDN18.2蛋白免疫小鼠,筛选出高亲和力单克隆抗体,在胃癌异种移植模型中显著抑制肿瘤生长,展现治疗潜力。

---

**注**:以上文献为示例,实际引用需核实真实存在的论文。若需进一步精准检索,建议结合PubMed或Web of Science等数据库,使用关键词“CLDN18.2 recombinant protein”或“recombinant Claudin-18”。

背景信息

Claudin-18 (CLDN18) is a member of the claudin family, transmembrane proteins critical for forming tight junctions that regulate paracellular barrier function and ion selectivity in epithelial and endothelial tissues. CLDN18 exists as two major splice variants: CLDN18.1. predominantly expressed in lung alveolar epithelium, and CLDN18.2. which localizes to gastric mucosa. These isoforms share structural features, including four transmembrane domains and two extracellular loops, but differ in tissue-specific roles. CLDN18.2. in particular, has gained attention due to its aberrant expression in gastric, esophageal, and pancreatic cancers, making it a promising therapeutic target.

Recombinant CLDN18 proteins are engineered using expression systems like mammalian cells (e.g., HEK293 or CHO cells) or bacteria (e.g., E. coli) to ensure proper folding and post-translational modifications. These proteins retain functional epitopes, enabling applications in antibody development, drug screening, and mechanistic studies of tight junction dynamics. For instance, recombinant CLDN18.2 is pivotal in developing monoclonal antibodies (e.g., zolbetuximab) that selectively target cancer cells overexpressing this isoform, minimizing off-target effects.

In research, recombinant CLDN18 proteins help elucidate its role in maintaining epithelial integrity, modulating immune responses, and influencing cancer metastasis. Dysregulation of CLDN18 is linked to pathologies such as chronic inflammation, fibrosis, and tumor progression. Additionally, CLDN18.2-specific recombinant proteins underpin diagnostic assays to identify patients eligible for targeted therapies. Despite challenges in preserving conformational stability during production, advances in protein engineering continue to enhance their utility in both basic science and clinical translation, solidifying CLDN18’s relevance in precision oncology and epithelial biology.

客户数据及评论

折叠内容

大包装询价

×